EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology

Christian Rummey, Gilbert Thomas-Black, Hector Garcia-Moreno, David R Lynch, Rosella Abeti, Huseyin Arisoy iD, Amanda Heslegrave, Henrik Zetterberg, Paola Giunti iD, European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)

Movement Disorders · 2025-09 · 40 (9) · 1863-1873

DOI: 10.1002/mds.30250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 11.06.2025. Verfasst von Christian Rummey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Data Science GmbH, Basel, Switzerland. Hauptthemen laut MEDLINE: Friedreich Ataxia, Biomarkers, tau Proteins, Neurofilament Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic interventions in Friedreich's ataxia (FRDA) are progressing into clinical trials, and the need for robust and easily accessible biomarkers has arisen.

Objective

This study aimed to consolidate preliminary findings of changes in the levels of neurofilament light (NfL), glial fibrillary acidic protein (GFAP), Tau, and ubiquitin C‐terminal hydrolase L1(UCH‐L1) in FRDA comparing two large independent cohorts of patients with healthy controls.

Methods

Plasma samples of patients from two large natural history studies (n = 187) and a similar sized cohort of healthy control subjects (n = 127) were assessed using single‐molecule array measurements. Age‐adjusted biomarker levels were related to patients’ genetic profile, clinical progression, and comorbidities, and compared with controls. Sensitivity and specificity were assessed using receiver operating characteristic analyses.

Results

NfL levels were significantly elevated in patients with FRDA younger than 40 years, showing a distinct age‐dependent trajectory: levels declined with age in FRDA but increased in controls. Longitudinal data indicated annual NfL reductions between 8% (children) and 13% (young adults < 35 years). This result is discussed in the context of other neurodegenerative conditions, with FRDA being a rare case where NfL levels decrease over time before the age of 40 years. In contrast, tau was consistently elevated across all age groups in FRDA.

Conclusions

NfL is a sensitive biomarker in early FRDA but decreases with age, converging with control values after 35–40 years. This age‐dependent pattern must be considered when interpreting the effect of interventions in clinical trials. Especially in younger (age < 10 years) or presymptomatic patients and control subjects, additional longitudinal sampling is warranted. Elevated tau levels suggest involvement in underlying disease pathophysiology. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Friedreich AtaxiaBiomarkerstau ProteinsNeurofilament ProteinsGlial Fibrillary Acidic ProteinUbiquitin ThiolesteraseHumansMaleAdultFemaleMiddle AgedYoung AdultAdolescentChildDisease ProgressionAged

Stichwörter der Autor:innen

Friedreich's ataxiaataxiabiomarkersneurofilament light

Substanzen

Biomarkerstau ProteinsNeurofilament Proteinsneurofilament protein LGlial Fibrillary Acidic ProteinUbiquitin ThiolesteraseGFAP protein, human

Autor:innen und Institutionen

  • Clinical Data Science GmbH, Basel, Switzerland.
  • The Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, London, United Kingdom.
  • National Hospital for Neurology and Neurosurgery, University College London Hospitals Foundation NHS Trust, London, United Kingdom.
  • Department of Pediatrics and Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
  • Dementia Research Institute, London, United Kingdom.

ORCID-Profile: Huseyin Arisoy, Paola Giunti

Zitieren

APA

Rummey, C., Thomas-Black, G., Garcia-Moreno, H., Lynch, D. R., Abeti, R., Arisoy, H., Heslegrave, A., Zetterberg, H., Giunti, P., & European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) (2025). Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology. Movement Disorders, 40(9), 1863-1873. https://doi.org/10.1002/mds.30250

Vancouver

Rummey C, Thomas-Black G, Garcia-Moreno H, Lynch DR, Abeti R, Arisoy H, et al. Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology. Movement Disorders. 2025;40(9):1863-1873. doi:10.1002/mds.30250

BibTeX
@article{Rummey2025,
  author = {Rummey, Christian and Thomas-Black, Gilbert and Garcia-Moreno, Hector and Lynch, David R and Abeti, Rosella and Arisoy, Huseyin and Heslegrave, Amanda and Zetterberg, Henrik and Giunti, Paola and European Friedreich's Ataxia Consortium for Translational Studies (EFACTS), European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)},
  title = {Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology},
  journal = {Movement Disorders},
  year = {2025},
  volume = {40},
  number = {9},
  pages = {1863--1873},
  doi = {10.1002/mds.30250}
}
Kostenlos starten →